Press release
Global Neuroblastoma Market Outlook 2025-2034: Trends, Innovations, And Future Outlook
Neuroblastoma Market
What Is the Neuroblastoma Market Size and Projected Growth Rate?
The neuroblastoma market's scale has been noticeably expanding in the past few years. It is projected to increase from $2.97 billion in 2024 to $3.15 billion in 2025, at a compound annual growth rate (CAGR) of 6.1%. The historical growth can be credited to an increase in the number of neuroblastoma cases, surge in research and development for pediatric neuroblastoma treatments, a rise in cases of childhood cancer, and a growth in government funding and aid.
Strong escalation is anticipated for the neuroblastoma market size in the upcoming years, with predictions stating it will reach a significant value of $3.93 billion in 2029, growing at a compound annual growth rate (CAGR) of 5.7%. The proliferation during the forecast period is attributed to factors like heightened government funding, rising disease prevalence, a concentrated effort on early detection, surged instances of genetic mutations, and an enhanced understanding thanks to research advancements. The forecast period will also see trends like the invention of drugs aimed at specific molecular pathways, breakthroughs in non-invasive imaging technologies, progress in gene-editing technologies, amplified focus on tailored treatment, and the creation of radiolabeled compounds.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20901
What Are the Major Segments in the Neuroblastoma Market?
The neuroblastoma market covered in this report is segmented -
1) By Product Types: Tablets, Vaccines, Other Product Types
2) By Treatment Type: Chemotherapy, Immunotherapy, Other Treatment Types
3) By Distribution Channel: Online, Offline
4) By End-User: Hospitals, Clinics
Subsegments:
1) By Tablets: Oral Chemotherapy Tablets, Targeted Therapy Tablets
2) By Vaccines: Immunotherapy Vaccines, Therapeutic Vaccines
3) By Other Product Types: Injectable Drugs, Monoclonal Antibodies, Cell Therapy Products
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20901&type=smp
What Are The Driving Neuroblastoma Market Evolution?
The escalation in the prevalence of cancer among children is predicted to foster the expansion of the neuroblastoma market. Childhood cancer, a group of malignancies that primarily impacts children and teens, often affects vital organs such as the brain, blood and bones, demanding specialized treatment strategies. This surge in childhood cancer is linked to elements like enhanced diagnostic methods, heightened awareness, environmental exposures, genetic tendencies, and progress in medical research. Treatment for neuroblastoma offers targeted therapies for such cancer in children, facilitating early and efficient interventions which reduce the chances of relapse and augment the results for young patients. For instance, the American Cancer Society, a US-based professional organization, projected that around 9,620 children under the age of 15 in the United States will be diagnosed with cancer in May 2024, a substantial increase from 5,290 cases in 2023. Hence, the escalating prevalence of cancer in children is propelling the expansion of the neuroblastoma market.
Which Firms Dominate The Neuroblastoma Market Segments?
Major companies operating in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Healio Inc., Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.
What Trends Are Expected to Dominate the Acquired Autoimmune Hemolytic Anemia Market in the Next 5 Years?
Leading firms in the neuroblastoma market are concentrating on the creation of sophisticated therapeutic options, specifically humanized anti-GD2 monoclonal antibodies, aiming to more effectively and securely combat cancer cells. A humanized anti-GD2 monoclonal antibody is innovatively designed to target GD2 molecules on cancer cells while reducing immune rejection through the integration of human elements. For instance, Renaissance Pharma Ltd., a British clinical-stage drug company, proclaimed the licensing in of Hu14.18K322A (Hu14.18) from St. Jude Children's Research Hospital in August 2023. This particular antibody is purposed for the treatment of newly diagnosed high-risk neuroblastoma, an uncommon and severe cancer prevalent in children. As per the agreement terms, Renaissance received sole rights to the development, production and commercialization of Hu14.18 in key international markets, including the United States, Canada, Europe, China, Japan, and Turkey.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/neuroblastoma--global-market-report
Which Is The Largest Region In The Neuroblastoma Market?
North America was the largest region in the neuroblastoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroblastoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Neuroblastoma Market?
2. What is the CAGR expected in the Neuroblastoma Market?
3. What Are the Key Innovations Transforming the Neuroblastoma Industry?
4. Which Region Is Leading the Neuroblastoma Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Neuroblastoma Market Outlook 2025-2034: Trends, Innovations, And Future Outlook here
News-ID: 4067518 • Views: …
More Releases from The Business Research Company
Emerging Drivers Influencing The Growth Of The Waylivra Market: Rising Prevalenc …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Waylivra Market Size Expected to Be by 2034?
In recent times, the market size of waylivra has experienced a XX (HCAGR). The market will escalate from $XX million in 2024 to $XX million in 2025, growing at a compound annual growth rate (CAGR) of XX%. The substantial growth…
Global Tubersol Market Analysis 2025-2030: Growth Drivers, Challenges, And Oppor …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Tubersol Market Size Expected to Be by 2034?
The size of the tubersol market has recently seen an XX (HCAGR) increase. Its growth is projected to escalate from $XX million in 2024 to $XX million in 2025, recording a compound annual growth rate (CAGR) of XX%. The expansion…
Global Novolin N Market Outlook 2025-2034: Drivers, Innovations, And Future Outl …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Novolin N Market Size Expected to Be by 2034?
In recent times, the market size of Novolin N has seen a significant increase of XX (HCAGR). Forecasts suggest that it will surge from $XX million in 2024 to $XX million in 2025, showing a Compound Annual Growth Rate…
Emerging Drivers Influencing The Growth Of The Zenpep Market: Rising Incidence O …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Zenpep Market Size Expected to Be by 2034?
The market size of Zenpep has experienced an XX (HCAGR) rise in recent years. The market, which was $XX million in 2024, is anticipated to grow to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%.…
More Releases for Neuroblastoma
Neuroblastoma Drugs Market Size, Share, Development by 2024
New report published by Global Info Research which offers insights on the Global Neuroblastoma Drugs market.
Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under…
Neuroblastoma - Pipeline Insight and Review, H1 2018
Market Research HUB has added a new report titled "Neuroblastoma - Pipeline Review, H1 2018, which provides an overview of the Neuroblastoma (Oncology) pipeline landscape. Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include…
Neuroblastoma Treatment Pipeline Review H2 2017
Pune, India, 27th November 2017: WiseGuyReports announced addition of new report, titled “Neuroblastoma - Pipeline Review, H2 2017”.
Summary
Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen…
Neuroblastoma - Pipeline Insight and Therapeutic Assessment Reviewed in 2017
A fresh report has been added to the wide database of Market Research Hub (MRH). The research study is titled “Neuroblastoma - Pipeline Review, H2 2017”which encloses important data about the production, consumption, revenue and market share, merged with information related to the market scope and product overview. The report anticipates that the sector for pharmaceutical industry would rise at a positive CAGR during the period 2017-2022.
Click here for Free…
Neuroblastoma Treatment Market to Register Substantial Expansion by 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…
Global Neuroblastoma Treatment Market: Latest Trends and Insights 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…
